Skip navigation

Current DateTime: 05:44:39 05 Dec 2008
LinksList Documentid: 24890560
  • Predictions '09

      Find out what trends, events, people and forces are likely to shape the world of business in 2009.

  • Holiday Central

      Your one stop destination for all the latest retail news, blog reports, shopping tips and holiday slideshows.

  • Wall Street In Crisis

      With shock after shock to the world's financial system, the credit crunch continues to drive a major reconfiguration of the Wall Street landscape.

Once-Weekly Diabetes Drug Lowers Blood Sugar: Study
Mike Huckman, | 09 Jun 2008 | 09:38 PM ET
Text Size

Eli Lilly, Amylin and Alkermes, partners on the first-ever once-a-week drug for diabetes, announced that patients saw their blood sugar go down by two percent and their weight drop an average nine-and-a-half pounds after one year on the experimental treatment.

In addition, nearly three-quarters of the diabetics in the study got their blood sugar level at or below the recommended threshold.

The companies plan to file for FDA approval of the once-a-week Byetta—currently marketed as a twice-a-day shot—by the end of the first half of next year.

Most analysts expect it to become a multi-billion dollar blockbuster.

The CEO of Amylin [AMLN  Loading...      ()   ], whose shares have been hammered the past two trading days, will appear first on CNBC Tuesday morning at 10:40 a.m. ET from the American Diabetes Association meeting in San Francisco where the data were presented.

Billionaire activist investor Carl Icahn recently took a sizeable stake in Amylin.

Shares of Eli Lilly [LLY  Loading...      ()   ] lost 0.5 percent to close at $48.18 Monday. Alkermes stock [ALKS  Loading...      ()   ] declined 1.67 percent to finish at $12.36.

© 2008 CNBC.com

HOME  |  NEWS  |  MARKETS  |  EARNINGS  |  INVESTING  |  VIDEO  |  CNBC TV  |  CNBC PLUS  |  CNBC MOBILE  |  CNBC HD+
About CNBC   |   Site Map   |   Privacy Policy   |   Terms of Service   |   Advertise   |   Help   |   Feedback   |   Video Reprints
  Data is a real-time snapshot   *Data is delayed at least 15 minutes

Global Business and Financial News, Stock Quotes, and Market Data and Analysis